0.6781 USD
+0.02 (+2.26%)
0.6601 USD
-0.02 (-2.65%)
We assign a fundamental rating of 2 out of 10 to VTGN. VTGN was compared to 530 industry peers in the Biotechnology industry. VTGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VTGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VTGN has reported negative net income.
In the past year VTGN has reported a negative cash flow from operations.
VTGN had negative earnings in each of the past 5 years.
VTGN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VTGN has a Return On Assets of -63.53%. This is in the lower half of the industry: VTGN underperforms 60.19% of its industry peers.
The Return On Equity of VTGN (-77.51%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.53% | ||
| ROE | -77.51% | ||
| ROIC | N/A |
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VTGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTGN has more shares outstanding than it did 1 year ago.
VTGN has more shares outstanding than it did 5 years ago.
VTGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VTGN has an Altman-Z score of -7.86. This is a bad value and indicates that VTGN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VTGN (-7.86) is worse than 67.55% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that VTGN is not too dependend on debt financing.
VTGN has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.86 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
A Current Ratio of 5.79 indicates that VTGN has no problem at all paying its short term obligations.
VTGN's Current ratio of 5.79 is fine compared to the rest of the industry. VTGN outperforms 60.94% of its industry peers.
VTGN has a Quick Ratio of 5.79. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
VTGN's Quick ratio of 5.79 is fine compared to the rest of the industry. VTGN outperforms 62.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.79 | ||
| Quick Ratio | 5.79 |
3. Growth
3.1 Past
VTGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.39%.
The Revenue for VTGN has decreased by -54.32% in the past year. This is quite bad
VTGN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.07% yearly.
EPS 1Y (TTM)-53.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%40.98%
3.2 Future
The Earnings Per Share is expected to grow by 27.75% on average over the next years. This is a very strong growth
VTGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 235.72% yearly.
EPS Next Y-11.54%
EPS Next 2Y9.5%
EPS Next 3Y16.44%
EPS Next 5Y27.75%
Revenue Next Year3.47%
Revenue Next 2Y144.6%
Revenue Next 3Y359.07%
Revenue Next 5Y235.72%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VTGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VTGN's earnings are expected to grow with 16.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.5%
EPS Next 3Y16.44%
5. Dividend
5.1 Amount
VTGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.6781
+0.02 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners50.11%
Inst Owner Change50.8%
Ins Owners0.19%
Ins Owner Change10.12%
Market Cap26.78M
Revenue(TTM)486.00K
Net Income(TTM)-51.42M
Analysts87.27
Price Target7.4 (991.28%)
Short Float %4.93%
Short Ratio0.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.29%
Min EPS beat(2)-11.22%
Max EPS beat(2)2.65%
EPS beat(4)3
Avg EPS beat(4)4.43%
Min EPS beat(4)-11.22%
Max EPS beat(4)14.73%
EPS beat(8)6
Avg EPS beat(8)11.06%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-29.62%
Min Revenue beat(2)-63.2%
Max Revenue beat(2)3.95%
Revenue beat(4)2
Avg Revenue beat(4)-31.78%
Min Revenue beat(4)-95.33%
Max Revenue beat(4)27.45%
Revenue beat(8)2
Avg Revenue beat(8)-31.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-50%
EPS NQ rev (1m)-40.9%
EPS NQ rev (3m)-32.03%
EPS NY rev (1m)-12.19%
EPS NY rev (3m)-12.19%
Revenue NQ rev (1m)-12.86%
Revenue NQ rev (3m)55.74%
Revenue NY rev (1m)41.35%
Revenue NY rev (3m)40%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 55.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.4 | ||
| P/tB | 0.4 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.9
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-1.35
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.01
BVpS1.68
TBVpS1.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.53% | ||
| ROE | -77.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | -327.69% | ||
| Cap/Sales | 43.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.79 | ||
| Quick Ratio | 5.79 | ||
| Altman-Z | -7.86 |
F-Score1
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)112.3%
Cap/Depr(5y)140.71%
Cap/Sales(3y)45.45%
Cap/Sales(5y)36.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y-11.54%
EPS Next 2Y9.5%
EPS Next 3Y16.44%
EPS Next 5Y27.75%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%40.98%
Revenue Next Year3.47%
Revenue Next 2Y144.6%
Revenue Next 3Y359.07%
Revenue Next 5Y235.72%
EBIT growth 1Y-69.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-68.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.14%
OCF growth 3YN/A
OCF growth 5YN/A
VISTAGEN THERAPEUTICS INC / VTGN FAQ
What is the fundamental rating for VTGN stock?
ChartMill assigns a fundamental rating of 2 / 10 to VTGN.
What is the valuation status of VISTAGEN THERAPEUTICS INC (VTGN) stock?
ChartMill assigns a valuation rating of 0 / 10 to VISTAGEN THERAPEUTICS INC (VTGN). This can be considered as Overvalued.
Can you provide the profitability details for VISTAGEN THERAPEUTICS INC?
VISTAGEN THERAPEUTICS INC (VTGN) has a profitability rating of 0 / 10.
What is the financial health of VISTAGEN THERAPEUTICS INC (VTGN) stock?
The financial health rating of VISTAGEN THERAPEUTICS INC (VTGN) is 4 / 10.
Can you provide the expected EPS growth for VTGN stock?
The Earnings per Share (EPS) of VISTAGEN THERAPEUTICS INC (VTGN) is expected to decline by -11.54% in the next year.